Updated Phase 1 Data for Daiichi Sankyo U3-1402 in Lung Cancer Presented

• Late-breaking results presented for U3-1402, a HER3 targeting ADC, in patients with metastatic EGFR mutated, TKI resistant NSCLC
• Manageable safety profile reported for U3-1402 with six confirmed partial responses and a reduction in tumor size in 22 of 26 evaluable patients across all doses
• Partial responses and tumor shrinkage observed in patients with diverse mechanisms of resistance
• Study to advance into dose expansion including additional cohort of patients with previously treated metastatic squamous or non-squamous NSCLC without EGFR mutation

https://www.biospace.com/article/releases/updated-phase-1-data-for-daiichi-sankyo-s-u3-1402-in-patients-with-egfr-mutated-nsclc-presented-at-2019-world-conference-on-lung-cancer/